Sign in
Explore the registryTrack Cabozantinib 140 mg's trials

EXAMINER

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Cabozantinib (XL184) 140 mgOngoingActive not recruitingPhase 4Open NCT01896479 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…